Summit Therapeutics Inc. (SMMT) just dropped some encouraging news for lung cancer patients and its own investors. The company announced that The Lancet Oncology published the primary analysis results from its global Phase 3 HARMONi trial, which tested ivonescimab combined with platinum-doublet chemotherapy against a placebo plus chemotherapy regimen.
The study zeroed in on a specific group: patients with epidermal growth factor receptor (EGFR)-mutated, locally advanced, or metastatic non-squamous non-small cell lung cancer (NSCLC) who had already progressed after using a third-generation EGFR tyrosine kinase inhibitor. These are folks who have run out of easy options, so any meaningful improvement is a big deal.
And the numbers are pretty compelling. Patients on the ivonescimab combo had a median progression-free survival (PFS) of 6.8 months, compared to 4.4 months for the placebo group. That's a hazard ratio of 0.52, which is a fancy way of saying the risk of progression or death was nearly halved. Independent reviewers confirmed the findings, and the benefit held up across preplanned subgroups.
Now, the overall survival (OS) data is a bit more nuanced. The primary OS analysis showed a positive trend, but it didn't hit statistical significance at that point. That's not unusual in these trials, but it's something to watch. The company later shared an updated OS analysis based on a June 2026 data cut-off, and that follow-up showed a continued positive trend, with a hazard ratio of 0.76 for Western patients. The safety profile stayed manageable, with severe treatment-related hemorrhage events occurring in less than 1% of patients.
So what's next? Summit will present more details from the updated analysis at the 2026 World Conference on Lung Cancer on September 15. That's a key moment for the data to get a public airing. And then there's the FDA. The agency has assigned a November 14, 2026 action date for the company's Biologics License Application. That's the big regulatory milestone that could determine whether this drug reaches the market.
In the meantime, there's some international momentum. In August, Summit's partner Akeso Inc. noted that China approved ivonescimab in combination with chemotherapy for the first-line treatment of patients with advanced squamous non-small cell lung cancer. That's a different patient population, but it shows the drug's potential beyond the current trial.
Investors seem to like what they're seeing. Summit Therapeutics shares were up 4.05% at $13.24 at the time of publication on Tuesday, according to market data.
The road ahead is clear: a data presentation in September, an FDA decision in November, and a lot of hopes riding on both. For now, the PFS numbers are solid, the OS trend is encouraging, and the safety profile looks manageable. That's a good place to be, but the real test is still to come.
